Pfizer Inc. (NYSE:PFE) is one of the best undervalued stocks under $50 to invest in now. Pfizer Inc. (NYSE:PFE) announced on ...
Investing.com -- Damora Therapeutics Inc (NASDAQ:DMRA) shares jumped 15.5% Monday following the announcement of Jennifer ...
Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead ...
Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of ...
High‑yield healthcare stocks are pulling back. See five dividends paying 6% to 14.1% and what their fundamentals reveal for ...
Pfizer reported positive Phase 3 results for TALZENNA (talazoparib) in combination with XTANDI in HRR gene mutated metastatic ...
Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose ...
MedPage Today on MSN
Cancer vaccines dogged by misinformation; 867-5309 for cancer; bee venom as therapy?
News, features, and commentary about cancer-related issues ...
Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...
Phase 3 TALAPRO-3 results show that talazoparib plus enzalutamide significantly improves radiographic progression-free ...
Clinical benefits of the talazoparib and enzalutamide combination extend to patients with both BRCA and non-BRCA homologous recombination repair gene alterations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results